ReviewTransplantation and cellular therapy2025
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.
Review in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.Bone marrow transplantation · 2026Guideline
- GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches.Human immunology · 2026Article
- Clonal Dynamics After Allogeneic Hematopoietic Stem Cell Transplantation from Related Donors: A Case Series.International journal of molecular sciences · 2026Article
- Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: Evolving Indications, Conditioning Strategies, and Outcomes.Hematology reports · 2026Review
- Donor Source Selection in Hematopoietic Cell Transplantation: Practices and Perceptions Across 50 United States Transplant Centers.Transplantation and cellular therapy · 2026Article
- Classical HLA allele and haplotype frequency estimates in US populations.Human immunology · 2026Article
- Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- System-level Redesign of an Allogeneic Hematopoietic Cell Transplantation Program Associated With High One-year Survival and Reduced Cost.Transplantation and cellular therapy · 2026Article
- Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy.Current opinion in immunology · 2026Review
- Uncoupling toxicity from efficacy in donor selection for allogeneic hematopoietic cell transplantation: a retrospective cohort study using double machine learning.Journal of hematology & oncology · 2026Article
- Classical HLA Allele and Haplotype Frequency Estimates in US Populations.bioRxiv : the preprint server for biology · 2026Article
- Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2026Article
- Recommendations for HLA Genotyping Data Standards and Clinical Laboratory Staffing Considerations.HLA · 2026Review
- A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.Blood advances · 2026Article
- Identification and management of the backup donor: recommendations from the World Marrow Donor Association.Bone marrow transplantation · 2026Review
- Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.HLA · 2026Article
- Article
- Article
- Advances inFrontiers in immunology · 2026Article
- Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.Transplantation and cellular therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure syndromes, inborn errors of immunity and metabolic disorders. Current donor selection strategies typically prioritize the selection of an HLA-matched donor over HLA mismatched ("alternative") donor sources, with a hierarchical approach to the donor search. More recent data challenge this rubric, particularly in the context of novel graft-versus-host disease (GVHD) prophylaxis strategies that demonstrate improved outcomes in alternative donor HCT recipients. In this setting, an increased emphasis on non-HLA factors (both donor characteristics and systemic factors) in determining donor selection is now feasible. In this guideline, we review recent evidence from prospective clinical trials as well as high-quality observational studies and provide expert panel recommendations on donor selection algorithms and prioritization in the era of novel GVHD prophylaxis. We then highlight important questions still to be answered in our field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.